A Phase 1b/2a Trial of FW 420 for the Treatment of Immune Checkpoint Inhibitor-Associated Colitis (ICI-AC)
Latest Information Update: 29 May 2024
At a glance
- Drugs Niclosamide (Primary)
- Indications Colitis
- Focus Therapeutic Use
- 16 May 2024 According to an Entero Therapeutics media release, First Wave Biopharma has changed its name to Entero Therapeutics.
- 16 Nov 2021 According to a AzurRx BioPharma media release, the company expect to initiate this study in 2022.
- 18 Feb 2021 According to a company pipeline, phase 1b trial is expected to launch in 1H 2021 and phase 2a trial is expected to be completed in Q4 22.